Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
申请人:University of Pittsburgh—Of the Commonwealth System of Higher Education
公开号:US10980806B2
公开(公告)日:2021-04-20
A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I:
R20—(Z)b—(Y)c—(R21)a—(X)d—R22—R23
wherein R20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(═O), —S(═O)(═O)—, or NR10, wherein R10 is H or alkyl; R21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, cycloalkenediyl, substituted cycloalkenediyl, alkatrienyl, substituted alkatrienyl; X is —C(═O)—, —S(═O)(═O)—, or —N(H)C(═O)—; R22 includes at least one divalent amino radical; R23 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; a, b, c, and d independently are 0 or 1.
一种符合式 I 的化合物或其药学上可接受的盐或酯:
R20-(Z)b-(Y)c-(R21)a-(X)d-R22-R23
其中 R20 是芳基、取代的芳基、杂芳基、取代的杂芳基、环烷基、取代的环烷基、杂环烷基、取代的杂环烷基、烷氧基、芳氧基、含硫基的基团或含硒基的基团;Z 是烷二基、取代的烷二基、环烷二基或取代的环烷二基; Y 是 S、O、S(═O)、-S(═O)(═O)- 或 NR10,其中 R10 是 H 或烷基;R21是烷二基、取代的烷二基、环烷二基、取代的环烷二基、烷二烯基、取代的烷二烯基、环烷二基、取代的环烷二基、烷三烯基、取代的烷三烯基;X是-C(═O)-、-S(═O)(═O)-或-N(H)C(═O)-;R22 包括至少一个二价氨基; R23 是芳基、取代的芳基、杂芳基、取代的杂芳基、环烷基、取代的环烷基、杂环烷基、取代的杂环烷基、烷氧基、芳氧基、含硫醚基团或含硒基团;a、b、c 和 d 独立地为 0 或 1。